Sair Y, Sair A
Psychiatry Clin Psychopharmacol. 2024; 32(3):222-228.
PMID: 38766675
PMC: 11099617.
DOI: 10.5152/pcp.2022.21129.
Pittenger C, Brennan B, Koran L, Mathews C, Nestadt G, Pato M
Psychiatry Res. 2021; 300:113853.
PMID: 33975093
PMC: 8536398.
DOI: 10.1016/j.psychres.2021.113853.
Alger J, ONeill J, OConnor M, Kalender G, Ly R, Ng A
Neurotox Res. 2021; 39(4):1054-1075.
PMID: 33751467
PMC: 8442735.
DOI: 10.1007/s12640-021-00342-0.
De Salles Andrade J, Ferreira F, Suo C, Yucel M, Frydman I, Monteiro M
Front Hum Neurosci. 2019; 13:186.
PMID: 31333428
PMC: 6620433.
DOI: 10.3389/fnhum.2019.00186.
ONeill J, OConnor M, Yee V, Ly R, Narr K, Alger J
Birth Defects Res. 2019; 111(12):797-811.
PMID: 30694611
PMC: 6650301.
DOI: 10.1002/bdr2.1460.
Glutamate Concentration in the Superior Temporal Sulcus Relates to Neuroticism in Schizophrenia.
Balz J, Roa Romero Y, Keil J, Schubert F, Ittermann B, Mekle R
Front Psychol. 2018; 9:578.
PMID: 29867621
PMC: 5949567.
DOI: 10.3389/fpsyg.2018.00578.
Disrupted Glutamatergic Transmission in Prefrontal Cortex Contributes to Behavioral Abnormality in an Animal Model of ADHD.
Cheng J, Liu A, Shi M, Yan Z
Neuropsychopharmacology. 2017; 42(10):2096-2104.
PMID: 28176786
PMC: 5561342.
DOI: 10.1038/npp.2017.30.
Attenuation of Compulsive-Like Behavior Through Positive Allosteric Modulation of α4β2 Nicotinic Acetylcholine Receptors in Non-Induced Compulsive-Like Mice.
Mitra S, Mucha M, Khatri S, Glenon R, Schulte M, Bult-Ito A
Front Behav Neurosci. 2017; 10:244.
PMID: 28105008
PMC: 5214813.
DOI: 10.3389/fnbeh.2016.00244.
Comorbidity Between Attention Deficit/Hyperactivity Disorder and Obsessive-Compulsive Disorder Across the Lifespan: A Systematic and Critical Review.
Abramovitch A, Dar R, Mittelman A, Wilhelm S
Harv Rev Psychiatry. 2015; 23(4):245-62.
PMID: 26052877
PMC: 4495876.
DOI: 10.1097/HRP.0000000000000050.
The neurobiological link between OCD and ADHD.
Brem S, Grunblatt E, Drechsler R, Riederer P, Walitza S
Atten Defic Hyperact Disord. 2014; 6(3):175-202.
PMID: 25017045
PMC: 4148591.
DOI: 10.1007/s12402-014-0146-x.
A cholinergic hypothesis of the unconscious in affective disorders.
Vakalopoulos C
Front Neurosci. 2013; 7:220.
PMID: 24319409
PMC: 3837351.
DOI: 10.3389/fnins.2013.00220.
Decreased Hepatocyte Growth Factor (HGF) and Gamma Aminobutyric Acid (GABA) in Individuals with Obsessive-Compulsive Disorder (OCD).
Russo A, Pietsch S
Biomark Insights. 2013; 8:107-14.
PMID: 24023510
PMC: 3762604.
DOI: 10.4137/BMI.S11931.
In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).
Haghighi M, Jahangard L, Mohammad-Beigi H, Bajoghli H, Hafezian H, Rahimi A
Psychopharmacology (Berl). 2013; 228(4):633-40.
PMID: 23525525
DOI: 10.1007/s00213-013-3067-z.
The uncompetitive NMDA receptor antagonists ketamine and memantine preferentially increase the choice for a small, immediate reward in low-impulsive rats.
Cottone P, Iemolo A, Narayan A, Kwak J, Momaney D, Sabino V
Psychopharmacology (Berl). 2012; 226(1):127-38.
PMID: 23104264
PMC: 3572289.
DOI: 10.1007/s00213-012-2898-3.
Investigation of cortical glutamate-glutamine and γ-aminobutyric acid in obsessive-compulsive disorder by proton magnetic resonance spectroscopy.
Simpson H, Shungu D, Bender Jr J, Mao X, Xu X, Slifstein M
Neuropsychopharmacology. 2012; 37(12):2684-92.
PMID: 22850733
PMC: 3473334.
DOI: 10.1038/npp.2012.132.
The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence.
Sani G, Serra G, Kotzalidis G, Romano S, Tamorri S, Manfredi G
CNS Drugs. 2012; 26(8):663-90.
PMID: 22784018
DOI: 10.2165/11634390-000000000-00000.
Adults with attention-deficit/hyperactivity disorder - a brain magnetic resonance spectroscopy study.
Dramsdahl M, Ersland L, Plessen K, Haavik J, Hugdahl K, Specht K
Front Psychiatry. 2011; 2:65.
PMID: 22131979
PMC: 3222884.
DOI: 10.3389/fpsyt.2011.00065.
The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder.
Wu K, Hanna G, Rosenberg D, Arnold P
Pharmacol Biochem Behav. 2011; 100(4):726-35.
PMID: 22024159
PMC: 3437220.
DOI: 10.1016/j.pbb.2011.10.007.
Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.
Pittenger C, Bloch M, Williams K
Pharmacol Ther. 2011; 132(3):314-32.
PMID: 21963369
PMC: 3205262.
DOI: 10.1016/j.pharmthera.2011.09.006.
Obsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatments.
Fontenelle L, Oostermeijer S, Harrison B, Pantelis C, Yucel M
Drugs. 2011; 71(7):827-40.
PMID: 21568361
DOI: 10.2165/11591790-000000000-00000.